Alveogene

Inhaled gene therapy development for patients with rare respiratory diseases

Oxford, United KingdomFounded 2022alveogene.comWebsite technologies

+ Add to sales board

Highlights

  • Young companyFounded 2022
  • New on EvolcAdded 2026-11-11

About Alveogene

AlveoGene develops inhaled gene therapies for serious respiratory diseases using its InGenuiTy platform, a licensed lentiviral delivery platform intended to target lung cells. Therapies can be delivered by nebuliser or, for neonates, through endotracheal tubing.

The company was created by Oxford Science Enterprises, Harrington Discovery Institute, Old College Capital and six scientists from the UK Respiratory Gene Therapy Consortium. It holds an exclusive licence to the platform for respiratory diseases, excluding use of the CFTR gene.

Product: Development of inhaled lentiviral gene therapies for serious respiratory diseases using the InGenuiTy platform.

Jobs at Alveogene

No open positions listed right now.

Leadership

More biotech & pharma companies

  • Amaxa

    Pharmaceutical company supplying prescription and OTC medicines to specialist markets across Europe, Central Asia and the Middle East
    London, United KingdomBiotech & pharmaFounded 2018
  • Amgen

    Biotechnology company developing and manufacturing biologic medicines for serious illnesses, with UK sites in Cambridge and Uxbridge
    Cambridge, United KingdomBiotech & pharmaFounded 1989
  • Aminoanalytica

    AI-enabled, field-ready diagnostics for emerging biological threats, supporting earlier pandemic detection and response
    London, United KingdomBiotech & pharmaFounded 2024
    Young companyNew on Evolc
  • Amo Pharma

    Develops investigational treatments for serious diseases, particularly rare genetic disorders, for patients with unmet medical needs
    Leeds, United KingdomBiotech & pharmaFounded 2015
    New on Evolc
  • Amped PCR

    QPCR reagents and custom formulations for research labs, assay developers and molecular testing partners
    Aberystwyth, United KingdomBiotech & pharmaFounded 2022
    Young companyNew on Evolc
  • Amphista Therapeutics

    Targeted protein degradation drug developer building Targeted Glue degraders for oncology, led by AMX-883 for AML
    Cambridge, United KingdomBiotech & pharmaFounded 2017

All biotech & pharma companies →

Website technologies

Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.

Content delivery

Content management

  • ElementorHigh confidence
    First detected
    Last detected
    Last checked
    Detection evidence
  • WordPressHigh confidence
    First detected
    Last detected
    Last checked
    Detection evidence

Frontend frameworks

  • jQueryHigh confidence
    First detected
    Last detected
    Last checked
    Detection evidence

Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.